The present invention relates to the field of medicine, in particular to a novel use of phenobarbital (PhB) in the treatment of autonomic dysregulation disorders. Long-term treatment reduces the sympathetic hyperactivity encountered during tests for stimulating the sympathetic system. The functional clinical improvement as well as the reduction of sympathetic hyperactivity, which was the goal of the sympathetic stimulation tests using low doses of phenobarbital, was remarkable in the preliminary...

This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to a pharmaceutical composition showing anticonvulsant activity on the basis of phenobarbital and a non-steroidal anti-inflammatory agent (fenamate) taken in molar ratio 23:5. The pharmaceutical composition is presented in the form of a dosage form for parenteral introduction and contains sodium phenobarbital 233 mg, sodium mefenamate 31.0 mg or sodium tolfenamate 33.5 mg, 1,2-propylene glycol 400 mg and ethanol 100 mg as stabilisers ...

The phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy, in particular epilepsy characterised by generalised seizures or temporal lobe seizures where the CBDV may be used in an isolated form or as a botanical drug substance. Preferably, CBDV is used with one or more therapeutically effective phytocannabinoids such as tetrahydrocannabivarin (THCV) and cannabidiol (CBD), and in combination with a standard anti-epileptic drug selected from ethosuximide, valproate or phenobarbital. A...